Martin Heslin, MD
Surgical Oncology · Mobile, ALNPI 1134156441
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Johnson & Johnson at 26.6% of the total. Reporting peaked in 2022 at $829 and has fallen 90.3% since, to $81 in 2024.
Across 76 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$387
- Incyte Corporation$136
- Eisai Inc.$128
- Intuitive Surgical$128
- Regeneron Healthcare Solutions, Inc.$126
- Tempus AI, Inc$63
- plus $490 from 22 others
What the payments were for
- Food & beverage$1,458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 22 | $387 |
| Incyte Corporation | 5 | $136 |
| Eisai Inc. | 7 | $128 |
| Intuitive Surgical | 2 | $128 |
| Regeneron Healthcare Solutions, Inc. | 5 | $126 |
| Tempus AI, Inc | 4 | $63 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Seagen Inc. | 3 | $40 |
| Lilly USA, LLC | 3 | $37 |
| Merck | 2 | $35 |
| AstraZeneca | 2 | $33 |
| Amgen | 2 | $31 |
| Boehringer Ingelheim | 1 | $22 |
| Pfizer | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Beigene USA, Inc. | 1 | $19 |
| Macrogenics, Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Immunogen, Inc. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $12 |
| Myovant Sciences Inc. | 1 | $11 |
How this compares
$1,458 in reported general payments places this provider in the 60th percentile of 26 surgical oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin Sulfate | 17 | $99 |
| Metronidazole | 17 | $35 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Mobile
- John HowardMobile$20K
- Joe LilesMobile$4K
- Udai SibiaMobile$3K
- Natalie BathMobile$2K
- Mercy JimenezMobile$2K
- Lee ThompsonMobile$1K
- Rachel HunterMobile$910
- Jillian McCabeMobile$817
- Sophie DreamBirmingham$39K
- Annabelle FonsecaBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.